(182 days)
Not Found
No
The document describes a simple immunochromatographic test and does not mention any AI or ML components.
No
This device is an in vitro diagnostic immunoassay for detecting a THC metabolite in urine, which is used for screening drugs of abuse. It does not treat or alleviate any medical condition, therefore it is not a therapeutic device.
Yes
The 'Intended Use / Indications for Use' section explicitly states "For In vitro Diagnostic Use."
No
The device description explicitly states it is an "immunochromatographic test," which is a physical test strip, indicating it is a hardware device, not software-only.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use/Indications for Use: Both listed intended uses explicitly state "For In vitro Diagnostic Use".
- Device Description: The description mentions it's an "immunochromatographic test," which is a common method used in IVD devices for detecting substances in biological samples.
- Sample Type: The test is performed on "urine," which is a biological sample.
- Purpose: The purpose is to detect a substance (THC metabolite) in the urine to assist in screening for drugs of abuse. This is a diagnostic purpose performed outside of the body (in vitro).
N/A
Intended Use / Indications for Use
Immunoassay for the qualitative detection of THC metabolite, 11-nor-A2-THC-9-carboxylic acid, at the cut-off of 50 ng/mL in urine to assist in screening of drugs of abuse samples at home. For In vitro Diagnostic Use
Product codes (comma separated list FDA assigned to the subject device)
LDJ
Device Description
Status Stik™ THC is simple one step immunochromatographic test for the rapid, qualitative detection of THC.
LifeSign®Home Drug Test (THC) is simple one sten immunochromatographic test for the rapid, qualitative detection of THC.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Home Use (LifeSign®Home Drug Test (THC)), Professional Use (Status Stik™ THC, AccuSign®Stik THC, AccuStik™ THC, AccuSign® THC, Status DSTM THC, AccuStrip™ THC)
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The tests demonstrated 100 % correlation when 100 specimens (50 negative and 50 positive) were compared.
In a consumer study, LifeSign® Home Drug Test (THC) showed over 95% overall accuracy.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
100 % correlation (when compared to predicate for Status Stik)
over 95% overall accuracy (for LifeSign Home Drug Test)
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 862.3870 Cannabinoid test system.
(a)
Identification. A cannabinoid test system is a device intended to measure any of the cannabinoids, hallucinogenic compounds endogenous to marihuana, in serum, plasma, saliva, and urine. Cannabinoid compounds includedelta -9-tetrahydrocannabinol, cannabidiol, cannabinol, and cannabichromene. Measurements obtained by this device are used in the diagnosis and treatment of cannabinoid use or abuse and in monitoring levels of cannabinoids during clinical investigational use.(b)
Classification. Class II (special controls). A cannabinoid test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).
0
510(k) Summarv
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR Part 807.92.
The assigned 510(k) number is:
-
Date of Summary: Nov.30, 2001
-
Submitted by: Princeton BioMeditech Corperation 4242 U.S. Route 1, Monmouth Jct., NJ 08852 PHONE 732-274-1000 732-274-1010 FAX Contact Person: Jemo Kang
-
Device Name: Trade Names: Stick Device: Status Stik™ THC, AccuSign® Stik THC, AccuStik™ THC Card Device: AccuSign® THC, Status DS™ THC Strip Test: AccuStrip™ THC Common or Usual Name: Immunoassay for detection of THC in human urine Classification Name: Drugs of Abuse Analysis Systems, Toxicology (91DKE for Enzyme Immunoassay)
-
- Identification of legally marketed device to which claims equivalence: K990786 Status DS™DOA10 (MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)
-
- Device Description: Status Stik™ THC is simple one step immunochromatographic test for the rapid, qualitative detection of THC.
-
- Intended Use: Status Stik" THC is designed for the qualitative detection of THC metabolite, 11-nor-A -THC-9-carboxylic acid, at the cutoff of 50 ng/mL in human urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use.
-
- Substantial Equivalence: Status Stik™ THC is substantially equivalent to K990786; Status DS "DOA10. Both products use the same assay principle and immunochromatographic assay, and the same antibody to detect THC metabolite qualitatively. The detection cutoff level is the same. The tests demonstrated 100 % correlation when 100 specimens (50 negative and 50 positive) were compared. The difference is that Status Stik" THC detects THC only, while Status DS DOA10 detects nine other drugs of abuse in addition to THC.
- Conclusion: The device is substantially equivalent to the legally marketed device K990786, Status DS ""DOA10 (MET/OPI/COC/THC/PCP/BZO/ BAR/MTD/TCA/AMP).
1
510(k) Summarv
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of the SMDA 1990 and 21 CFR Part 807.92.
The assigned 510(k) number is:
- Date of Summary: Nov.30, 2001
-
- Submitted by: Princeton BioMeditech Corperation 4242 U.S. Route 1. Monmouth Jct., NJ 08852 PHONE 732-274-1000 FAX 732-274-1010 Contact Person: Jemo Kang
- Device Name: Trade Names: LifeSign®Home Drug Test (THC) Common or Usual Name: Immunoassay for detection of THC in human urine Classification Name: Drugs of Abuse Analysis Systems, Toxicology (91DKE for Enzyme Immunoassay)
-
- Identification of legally marketed device to which claims equivalence: K990786 Status DS ""DOA10(MET/OPI/COC/THC/PCP/BZO/BAR/MTD/TCA/AMP)
- LifeSign®Home Drug Test (THC) is simple one 5. Device Description: sten immunochromatographic test for the rapid, qualitative detection of THC.
-
- Intended Use: LifeSign®Home Drug Test (THC)is designed for the qualitative detection of THC metabolite. 11-nor-A-THC-9-carboxylic acid. at the cutoff of 50 ng/mL in human urine to assist in screening of drugs of abuse samples at home. For In vitro Diagnostic Use.
-
- Substantial Equivalence: LifeSign®Home Drug Test (THC) is substantially equivalent to K990786; Status DS DOA10. Both products use the same assay principle and immunochromatographic assay, and the same antibody to detect THC metabolite qualitatively. The detection cutoff level is the same. The tests demonstrated 100 % correlation when 100 specimens (50 negative and 50 positive) were compared. The difference is that LifeSign Home Drug Test (THC) detects THC only, while Status DS "DOA10 detects nine other drugs of abuse in addition to THC.
-
- Consumer Study: In a consumer study, LifeSign® Home Drug Test (THC) showed over 95% overall accuracy.
Conclusion: The device is substantially equivalent to the legally marketed device K990786. Status DS ""DOA10 (MET/OPI/COC/THC/PCP/BZO/ BAR/MTD/TCA/AMP).
2
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized eagle with three lines representing its body and wings. The words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle.
JUN 1 0 2002
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Jemo Kang, Ph.D. Director Princeton BioMeditech Corporation 4242 U.S. Route 1 Monmouth Junction, NJ 08852-1905
Re: K014066
Trade/Device Name: LifeSign®Home Drug Test (THC) Status Stik™ THC. AccuSign®Stik THC. AccuStik™ THC. AccuSign® THC, Status DSTM THC, Strip: AccuStrip™ THC Regulation Number: 21 CFR 862.3870 Regulation Name: Cannabinoid test system Regulatory Class: Class II Product Code: LDJ Dated: April 9, 2002 Received: April 10, 2002
Dear Dr. Kang:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 -
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and ' additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Butman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory-Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
| T | く
A
1
1 |
|---|------------------|
| | |
510(k) Number (if known): _ | ص ب ب 06
Device Name: __ LifeSign Home Drug Test (THC)
Indications For Use:
Immunoassay for the qualitative detection of THC metabolite, 11-nor-A2-THC-9-carboxylic acid, at the cut-off of 50 ng/mL in urine to assist in screening of drugs of abuse samples at home. For In vitro Diagnostic Use
(Division S-Off)
Division.mical Laboratory Devices
510(k) Number Koi14066
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH Office of Device Evaluation (ODE)
Professional Use:
Prescription Use:_____________________________________________________________________________________________________________________________________________________________ (Per 21 CFR 801.109)
OR
Over The Counter Use: _X
(Optional Format 1-2-96)
5
f
510(k) Number (if known): K014066
Device Name: Stick: Status Stik™ THC, AccuSign®Stik THC, AccuStik™ THC Card: AccuSign® THC, Status DSTM THC Strip: AccuStrip™ THC
510(k) Number "
Indications For Use:
Immunoassay for the qualitative detection of THC metabolite, 11-nor-A -THC-9-carboxylic acid, at the cut-off of 50 ng/mL in urine to assist in screening of drugs of abuse samples. For In vitro Diagnostic Use
Dan Cooper
(Division Sign-Off)
Division of Clinical Laboratory/Devices
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH Office of Device Evaluation (ODE)
Professional Use: | |
---|---|
Prescription Use: | X |
(Per 21 CFR 801.109)
OR
Over The Counter Use: ________________________________________________________________________________________________________________________________________________________
(Optional Format 1-2-96)